NASDAQ · SYRE
Spyre Therapeutics, Inc.
$96.02-$2.94 (-2.97%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.85% below the high.
Loading market information…
NASDAQ · BLUE · USD
Stock price, earnings
Quote as of Jun 2, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
bluebird bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.62% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow bluebird bio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating genetic conditions. Among its leading investigational therapies for severe inherited diseases are betibeglogene autotemcel (beti-cel), intended for patients with transfusion-dependent beta-thalassemia; lovotibeglogene autotemcel (lovo-cel), which targets sickle cell disease (SCD); and elivaldogene autotemcel (eli-cel), developed to address cerebral adrenoleukodystrophy. The company's robust clinical trial program is actively evaluating the safety and efficacy of these treatments. Specifically, lovo-cel's impact on SCD patients is being assessed in studies HGB-205, HGB-206, and HGB-210. Concurrently, beti-cel is under investigation for beta-thalassemia in trials HGB-204, HGB-205, HGB-207, and HGB-212. Furthermore, bluebird bio maintains strategic collaborations and licensing arrangements with entities such as Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company, which began its operations in 1992, was formerly known as Genetix Pharmaceuticals, Inc., and rebranded as bluebird bio, Inc. in September 2010. Its principal office is located in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:19 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2023 | Nov 7, 2023 | -$13.20-0.52% vs estimate | $12.39M-8.62% vs estimate |
|---|
| Q2 2023 | Aug 8, 2023 | -$13.40-0.21% vs estimate | $6.89M-39.04% vs estimate |
|---|
THE ANALYST VIEW
37 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$96.02-$2.94 (-2.97%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.85% below the high.
$0.68-$0.04 (-5.84%)
Rein Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.61% below the high.
$1.48$0.00 (0.0%)
TCR2 Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.86% below the high.
$0.88+$0.01 (+1.49%)
Kronos Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.73% below the high.
$9.81+$0.39 (+4.14%)
AlloVir, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.38% below the high.
$0.78+$0.01 (+1.3%)
ERYTECH Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 47.01% below the high.
$0.30-$0.00 (-0.03%)
GreenLight Biosciences Holdings’s quoted price sits in the lower half of its reported 52-week range, 94.92% below the high.
$0.70-$0.06 (-7.74%)
Magenta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.35% below the high.
